JPRN-UMIN000042164Completed未知
etwork meta-analysis for chemo-naive incurable not highly PD-L1-expressed non-squamous non-small cell lung cancer without confirmed driver alteration - Network meta-analysis for chemo-naive incurable not highly PD-L1-expressed non-squamous non-small cell lung cancer without confirmed driver alteration
Yokohama City University University Hospital0 sites16,391 target enrollmentStarted: October 20, 2020Last updated:
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Completed
- Enrollment
- 16,391
Study Overview
Brief Summary
Please see: Thorac Cancer. 2021 Nov 17. doi: 10.1111/1759-7714.14229.
Study Design
- Study Type
- Others,meta-analysis etc
Eligibility Criteria
- Ages
- ot applicable to ot applicable (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Kinase inhibitors targeting EGFR, ALK, ROS1, and BRAF are beyond our concern. A patient whose PD-L1 protein expression determined by tumor proportion score (TPS) is 50% or higher will be excluded because current guidelines recommends treatment option differently for those with TPS <50% and >=50%. If subset of study population fit our criteria, the data of the subset will be analyzed. For example, a study separately provide data of three populations whose TPS score is 0%, 1-49%, and 50-%, we will collect data of populations with TPS of 0% and 1-49%. Tumor mutation burden is not questioned. If a study focusses on patients with squamous NSCLC, driver alteration, or TPS of 50% or higher, the study should be excluded. However, a study without criteria regarding pathological subclassification of NSCLC, driver gene, and TPS is acceptable, otherwise most NSCLC studies will be excluded.
Investigators
Similar Trials
Completed
Not Applicable
etwork meta-analysis for chemo-naive incurable not highly PD-L1-expressed squamous non-small cell lung cancer without confirmed driver alteratiochemo-naive incurable not highly PD-L1-expressed squamous non-small cell lung cancer without confirmed driver alterationJPRN-UMIN000042163Yokohama City University University Hospital22,619
Not yet recruiting
Not Applicable
etwork meta-analysis of adjuvant chemotherapy for NSCLCEarly-stage non-small cell lung cancerJPRN-UMIN000042811Self sponsored
Completed
Phase 2
Induction Chemotherapy and Adjuvant Thoracic Radiation in Resectable Stage N2-3A/3B Non-small Cell Lung Cancer (ICAT study)Resectable Stage 3A-N2 Non-small Cell Lung CancerJPRN-UMIN000025010Kyoto Prefectural University of Medicine1
Completed
Phase 4
A multicentre study using the chemotherapy combination of bi-monthly Xeloda and Eloxatin, with the addition of Avastin, in patients with advanced colorectal cancerCancerColorectal cancerISRCTN41540878Cancer Trials New Zealand (CTNZ)60
Completed
Not Applicable
Prognostic Indicators for Conventional Chemotherapy Response in Advanced Non-Small Cell Lung Cancer Patients in Resource-Limited CountrySCLC patients with unresectable stage IIIB or IV by TNM 7th edition who were treated with platinum-based doublet chemotherapy as first line treatmentnon small cell lung cancer, prognostic factor, chemotherapyTCTR20220131001A207